Smoore International Holdings (SMORF) Fair Value & Analysis
Consumer Defensive · US · Market cap $8.7B
Analysis
Smoore International Holdings (SMORF) currently trades at $1.40, while our model-based Fair Value estimate is $0.8200 — implying the stock looks roughly 41.4% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Smoore International Holdings Limited, an investment holding company, engages in the provision of vaping technology solutions. The company is involved in the research, design, and manufacture of vaping, heat-not-burn, atomization, and inhalation therapy products for tobacco companies, independent vaping brands, and other corporate clients. It also engages in the research, design, manufacturing, and sales of self-branded electronic vaping products and beauty atomization products. In addition, the company offers vaping solutions under the FEELM brand; vaping products under the VAPORESSO brand; and HTP atomization solutions under the METEX brand. Further, it is involved in the operation of supply chain services; research and development; and trustee activities. The company operates in Hong Kong, China, the United Kingdom, the United States, Mainland China, France, Japan, Croatia, the United Arab Emirates, and internationally. Smoore International Holdings Limited was founded in 2009 an…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.